The P-II study evaluating QL1706 + CT and bevacizumab in 100 patients with stage IIIB/C & stage IV with wild-type & mutated EGFR
Among 29 & 31 patients treated with QL1706 (5mg/kg, q3w) + CT with wild-type EGFR & with mutated EGFR for 2 & 4 cycles and then QL1706 (5mg/kg, q2w) for maintenance therapy until disease progression or other discontinuation events showed the median follow-up was 9.17mos. & 5.75mos., ORR was 58.6% (70.6% in sq. NSCLC cohort; 41.7% in non-sq. cohort) & 64.5%; DCR (93.1% & 93.5%), respectively
m-PFS was 6.97mos. in patients with wild-type EGFR while PFS was not yet mature & 6mos. PFS rate was 61.3% in mutated EGFR, AEs were manageable & the safety profile was consistent with that reported for CT or anti-PD-1 & anti-CTLA-4 therapy
Ref: PRNewswire | Image: Qilu Pharmaceutical
